Louisiana State Employees Retirement System Buys Shares of 16,300 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Louisiana State Employees Retirement System bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 16,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $502,000.

Several other hedge funds have also modified their holdings of COLL. SG Americas Securities LLC purchased a new stake in Collegium Pharmaceutical during the third quarter valued at approximately $221,000. Strs Ohio increased its position in shares of Collegium Pharmaceutical by 1,650.0% during the third quarter. Strs Ohio now owns 21,000 shares of the specialty pharmaceutical company’s stock worth $469,000 after purchasing an additional 19,800 shares in the last quarter. Inspire Investing LLC lifted its holdings in shares of Collegium Pharmaceutical by 3.2% during the 3rd quarter. Inspire Investing LLC now owns 27,840 shares of the specialty pharmaceutical company’s stock valued at $622,000 after purchasing an additional 873 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Collegium Pharmaceutical by 1,019.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,670 shares of the specialty pharmaceutical company’s stock worth $931,000 after purchasing an additional 37,946 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in Collegium Pharmaceutical by 0.8% during the 3rd quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company’s stock worth $1,718,000 after buying an additional 585 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

COLL opened at $36.71 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. Collegium Pharmaceutical, Inc. has a 12-month low of $20.83 and a 12-month high of $40.95. The firm has a 50 day moving average of $37.22 and a two-hundred day moving average of $31.47. The firm has a market capitalization of $1.20 billion, a PE ratio of 31.11 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The firm had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. On average, analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current year.

Analyst Ratings Changes

COLL has been the subject of a number of research analyst reports. StockNews.com upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th. Jefferies Financial Group restated a “hold” rating and set a $37.00 price target (up previously from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Truist Financial raised their price target on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, February 26th. Finally, Piper Sandler reissued an “overweight” rating and set a $39.00 price objective (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.